Edgewise Therapeutics, Inc.
EWTX
$11.42
-$0.15-1.30%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.69% | 10.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.63% | 6.10% | |||
| Operating Income | -12.63% | -6.10% | |||
| Income Before Tax | -16.21% | -8.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.21% | -8.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.21% | -8.36% | |||
| EBIT | -12.63% | -6.10% | |||
| EBITDA | -12.71% | -6.02% | |||
| EPS Basic | -15.09% | -8.02% | |||
| Normalized Basic EPS | -15.08% | -8.03% | |||
| EPS Diluted | -15.09% | -8.02% | |||
| Normalized Diluted EPS | -15.08% | -8.03% | |||
| Average Basic Shares Outstanding | 0.97% | 0.32% | |||
| Average Diluted Shares Outstanding | 0.97% | 0.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
